282 results on '"Castillo-Martin, Mireia"'
Search Results
2. PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer
3. circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment
4. Characterization and detection of colorectal cancer by multidimensional autofluorescence lifetime imaging: a preliminary study on surgical specimens
5. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
6. Case Studies: Molecular Pathology Perspective and Impact on Oncologic Patients’ Management
7. Gastric schwannoma: Two case reports and review of the literature
8. Dual excitation spectral autofluorescence lifetime and reflectance imaging for fast macroscopic characterization of tissues
9. Impact of PSMA PET/CT in prostate cancer patient’s clinical management: a pictorial essay of interesting cases with histologic confirmation
10. Salvage surgery for local regrowths in Watch & Wait - Are we harming our patients by deferring the surgery?
11. cT2N0 Distal Rectal Cancer: Do Not Believe in Fairy Tales
12. Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation
13. Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis
14. Intragenic antagonistic roles of protein and circRNA in tumorigenesis
15. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR
16. International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
17. Genomic Analysis of Epithelial Ovarian Cancer
18. Case Studies: Molecular Pathology Perspective and Impact on Oncologic Patients’ Management
19. Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling
20. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
21. Supplementary Figure 1 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
22. Supplementary Figure S6. Ar expression in primary and metastatic tumors. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
23. Supplementary Figure 3 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
24. Supplementary Figure S2. Genetic tools used for dissecting Il6/Stat3/Myc signaling. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
25. Supplementary Figure Legend from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
26. Data from Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis
27. Supplementary Figure Legends from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
28. Supplementary Figure Legend from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
29. Data from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
30. Supplementary Figure 6 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
31. Supplementary Figure S1. Copy Number Alteration analysis of human prostate cancer confirms loss of PTEN and TP53 genes as a genetic hallmark of metastatic prostate cancer. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
32. Supplementary Figure 8 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
33. Supplementary Figure S3. Tools used for targeting of Il6 and Stat3. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
34. Supplementary Figure 7 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
35. Supplementary Figure 1 from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
36. Supplementary Figure S5. IHC analysis of wild type lung and primary and metastatic tumors. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
37. Supplementary Figure S3 from Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis
38. Supplementary Figure Legends from Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis
39. Supplementary Figure S4. Activation of Stat3/Myc signaling is specific to Ptenpc-/-; Trp53pc-/-prostate and leads to stromal expansion. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
40. Supplementary Figure S7. Pathway to Pten/ Trp53 deficient prostate metastasis and therapy resistance. from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
41. Supplementary Figure Legends from A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells
42. Supplementary Figure 4 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
43. Supplementary Figures S1 - S5 from A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells
44. Data from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
45. Supplementary Figure 3 from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
46. Supplementary Figure 2 from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
47. Supplementary Figure 2 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
48. Supplementary Figure 5 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
49. Data from MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
50. Data from PPARδ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.